Yoichi Imai

Dr. Yoichi Imai

The Institute of Medical Science, The University of Tokyo
orcid

Research Focus & Metrics

Academic Career Length

35Years (1992-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2001 in Blood
Verified
Journal Article
Open access
PDF file
KIKoji Izutsu
Koji Izutsu
MKMineo Kurokawa
Mineo Kurokawa
YIYoichi Imai
Yoichi Imai
KMKazuhiro Maki
Kazuhiro Maki
KMKinuko Mitani
Kinuko Mitani
HHHisamaru Hirai
Hisamaru Hirai
Evi-1 is a zinc finger nuclear protein whose inappropriate expression leads to leukemic transformation of hematopoietic cells in mice and humans. This was previously shown to block the antiproliferative effect of transforming growth factor β (TGF-β). Evi-1 represses TGF-β signaling by direct interaction with Smad3 through its first zinc finger motif. Here, it is demonstrated that Evi-1 represses Smad-induced transcription by recruiting C-terminal binding protein (CtBP) as a corepressor. Evi-1 associates with CtBP1 through one of the consensus binding motifs, and this association is required for efficient inhibition of TGF-β signaling. A specific inhibitor for histone deacetylase (HDAc) alleviates Evi-1–mediated repression of TGF-β signaling, suggesting that HDAc is involved in the transcriptional repression by Evi-1. This identifies a novel function of Evi-1 as a member of corepressor complexes and suggests that aberrant recruitment of corepressors is one of the mechanisms for Evi-1–induced leukemogenesis.

14 November 2011 in Journal of Experimental Medicine
Verified
Journal Article
Open access
PDF file
KKKeisuke Kataoka
Keisuke Kataoka
TSTomohiko Sato
Tomohiko Sato
Akihide YoshimiAkihide Yoshimi
Akihide Yoshimi
SGSusumu Goyama
Susumu Goyama
TTTakako Tsuruta
Takako Tsuruta
MKMineo Kurokawa
Mineo Kurokawa
Ecotropic viral integration site 1 (Evi1), a transcription factor of the SET/PR domain protein family, is essential for the maintenance of hematopoietic stem cells (HSCs) in mice and is overexpressed in several myeloid malignancies. Here, we generate reporter mice in which an internal ribosome entry site (IRES)-GFP cassette is knocked-in to the Evi1 locus. Using these mice, we find that Evi1 is predominantly expressed in long-term HSCs (LT-HSCs) in adult bone marrow, and in the hematopoietic stem/progenitor fraction in the aorta-gonad-mesonephros, placenta, and fetal liver of embryos. In both fetal and adult hematopoietic systems, Evi1 expression marks cells with long-term multilineage repopulating activity. When combined with conventional HSC surface markers, sorting according to Evi1 expression markedly enhances purification of cells with HSC activity. Evi1 heterozygosity leads to marked impairment of the self-renewal capacity of LT-HSCs, whereas overexpression of Evi1 suppresses differentiation and boosts self-renewal activity. Reintroduction of Evi1, but not Mds1-Evi1, rescues the HSC defects caused by Evi1 heterozygosity. Thus, in addition to documenting a specific relationship between Evi1 expression and HSC self-renewal activity, these findings highlight the utility of Evi1-IRES-GFP reporter mice for the identification and sorting of functional HSCs.

31 March 2011 in Blood
Verified
Journal Article
Closed access
PDF file
Akihide YoshimiAkihide Yoshimi
Akihide Yoshimi
SGSusumu Goyama
Susumu Goyama
NWNaoko Watanabe-Okochi
Naoko Watanabe-Okochi
YYYumiko Yoshiki
Yumiko Yoshiki
YNYasuhito Nannya
Yasuhito Nannya
MKMineo Kurokawa
Mineo Kurokawa
Evi1 (ecotropic viral integration site 1) is essential for proliferation of hematopoietic stem cells and implicated in the development of myeloid disorders. Particularly, high Evi1 expression defines one of the largest clusters in acute myeloid leukemia and is significantly associated with extremely poor prognosis. However, mechanistic basis of Evi1-mediated leukemogenesis has not been fully elucidated. Here, we show that Evi1 directly represses phosphatase and tensin homologue deleted on chromosome 10 (PTEN) transcription in the murine bone marrow, which leads to activation of AKT/mammalian target of rapamycin (mTOR) signaling. In a murine bone marrow transplantation model, Evi1 leukemia showed modestly increased sensitivity to an mTOR inhibitor rapamycin. Furthermore, we found that Evi1 binds to several polycomb group proteins and recruits polycomb repressive complexes for PTEN down-regulation, which shows a novel epigenetic mechanism of AKT/mTOR activation in leukemia. Expression analyses and ChIPassays with human samples indicate that our findings in mice models are recapitulated in human leukemic cells. Dependence of Evi1-expressing leukemic cells on AKT/mTOR signaling provides the first example of targeted therapeutic modalities that suppress the leukemogenic activity of Evi1. The PTEN/AKT/mTOR signaling pathway and the Evi1-polycomb interaction can be promising therapeutic targets for leukemia with activated Evi1.

1 July 1996 in Molecular and Cellular Biology
Verified
Journal Article
Open access
PDF file
TTTomoyuki Tanaka
Tomoyuki Tanaka
MKMineo Kurokawa
Mineo Kurokawa
KUKohjiro Ueki
Kohjiro Ueki
Kozo TanakaKozo Tanaka
Kozo Tanaka
YIYoichi Imai
Yoichi Imai
HHHisamaru Hirai
Hisamaru Hirai
AML1 (also called PEBP2alphaB, CBFA2, or CBFalpha2) is one of the most frequently disrupted genes in chromosome abnormalities seen in human leukemias. It has been reported that AML1 plays several pivotal roles in myeloid hematopoietic differentiation and other biological phenomena, probably through the transcriptional regulation of various relevant genes. Here, we investigated the mechanism of regulation of AML1 functions through signal transduction pathways. The results showed that AML1 is phosphorylated in vivo on two serine residues within the proline-, serine-, and threonine-rich region, with dependence on the activation of extracellular signal-regulated kinase (ERK) and with interleukin-3 stimulation in a hematopoietic cell line. These in vivo phosphorylation sites of AML1 were phosphorylated directly in vitro by ERK. Although differences between wild-type AML1 and phosphorylation site mutants in DNA-binding affinity were not observed, we have shown that ERK-dependent phosphorylation potentiates the transactivation ability of AML1. Furthermore the phosphorylation site mutations reduced the transforming capacity of AML1 in fibroblast cells. These data indicate that AML1 functions are potentially regulated by ERK, which is activated by cytokine and growth factor stimuli. This study provides some important clues for clarifying unidentified facets of the regulatory mechanism of AML1 function.

2 April 2009 in International Journal of Hematology
Verified
Journal Article
Closed access
PDF file
KUKoki Ueda
Koki Ueda
YNYasuhito Nannya
Yasuhito Nannya
KKKeiki Kumano
Keiki Kumano
AHAkira Hangaishi
Akira Hangaishi
TTTsuyoshi Takahashi
Tsuyoshi Takahashi
MKMineo Kurokawa
Mineo Kurokawa

1 February 2009 in Transplantation and Cellular Therapy
Verified
Journal Article
Open access
KKKeisuke Kataoka
Keisuke Kataoka
YNYasuhito Nannya
Yasuhito Nannya
AHAkira Hangaishi
Akira Hangaishi
YIYoichi Imai
Yoichi Imai
SCShigeru Chiba
Shigeru Chiba
MKMineo Kurokawa
Mineo Kurokawa
Iron overload might be an important contributor to nonrelapse mortality (NRM) in hematopoietic stem cell transplantation (HSCT). We studied 264 patients undergoing allogeneic HSCT for hematologic malignancies between 1996 and 2006, using pretransplantation serum ferritin as a surrogate marker of iron overload. At 5 years, patients in the high ferritin group (>or= 599 ng/mL) had a lower overall survival (OS; 33.0% versus 63.5%; P< .001) and a higher NRM (34.9% versus 13.7%; P< .001) than those in the low ferritin group (<599 ng/mL). Multivariate analyses showed that high pretransplantation serum ferritin was a significant risk factor for worse survival (relative risk [RR]=1.68; P= .05) and increased NRM (RR=2.47; P= .01). There was no significant difference in the cumulative incidence of relapse, and acute and chronic graft-versus-host disease (aGVHD, cGVHD) between the 2 groups. Patients in the high ferritin group were more likely to die of infection (P< .010) and organ failure (P< .019). Similar results were observed after dividing the patients according to the intensity of conditioning regimens. These findings emphasize the prognostic impact of pretransplantation serum ferritin in HSCT recipients.